Acurx Pharmaceuticals (ACXP) Proxy Filing summary

Executive summary

• Special meeting scheduled for September 16, 2025, to be held virtually, allowing shareholders to vote and ask questions online.

• Key proposals include approval of share issuance under series G-2 warrants, an increase in authorized common stock, and potential adjournment to solicit more votes.

• Board recommends approval of all proposals to support future corporate flexibility and financing.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of shares underlying series G-2 warrants, potentially exceeding 20% of outstanding shares, to comply with Nasdaq rules.

• Proposal 2: Approve amendment to increase authorized common stock from 200,000,000 to 250,000,000 shares.

• Proposal 3: Approve adjournment of the meeting if more time is needed to solicit votes for the above proposals.

• Each proposal requires a majority of votes cast to pass; abstentions and broker non-votes generally have no effect.

Board of directors and corporate governance

• Board and management recommend voting in favor of all proposals.

• Shareholder communications can be directed to the Board via the corporate secretary.

• Security ownership table discloses holdings of directors, officers, and major shareholders as of July 23, 2025.